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Cost-Effectiveness Analysis of Needle Arthroscopy
Versus Magnetic Resonance Imaging in the Diagnosis
and Treatment of Meniscal Tears of the Knee
Nirav Amin, M.D., Louis McIntyre, M.D., Thomas Carter, M.D.,
John Xerogeanes, M.D., and Jeffrey Voigt, M.B.A., M.P.H.
Purpose: To determine whether needle arthroscopy (NA) compared with magnetic resonance imaging (MRI) in the
diagnosis and treatment of meniscal tears is cost-effective when evaluated over a 2-year period via patient-reported
outcomes. The hypothesis is that improved diagnostic accuracy with NA would lead to less costly care and similar out-
comes.Methods: A Markov model/decision tree analysis was performed using TreeAge Pro 2017 software. Patients were
evaluated for degenerative and traumatic damage to the lateral/medial meniscus. Assumed sensitivities and speciﬁcities
were derived from the medical literature. The direct costs for care were derived from the 2017 Medicare fee schedule and
from private payer reimbursement rates. Costs for care included procedures performed for false-positive ﬁndings and for
care for false-negative ﬁndings. Effectiveness was examined using the global knee injury and osteoarthritis outcome score
(KOOS). Patients were evaluated over 2 years for costs and outcomes, including complications. Dominance and incre-
mental cost-effectiveness were evaluated, and 1- to 2-way sensitivity analysis was performed to determine those variables
that had the greatest effect. The consolidated economics evaluation and reporting standards checklist for reporting eco-
nomic evaluations was used. Results: NA was less costly and had similar KOOS versus MRI for both the medial/lateral
meniscus with private pay. Costs were less for both Medicare and private pay for medial meniscus, $780 to $1,862, and
lateral meniscus, $314 to $1,256, respectively. Conclusions: Based on the reported MRI incidence of false positives with
the medial meniscus and false negatives with the lateral meniscus and based on assumed standards of care, more costly
care is provided when using MRI compared with NA. Outcomes were similar with NA compared with MRI. Level of
Evidence: Level II, economic and decision analysis.
See commentary on page 563
Magnetic resonance imaging (MRI) is thepredominant diagnostic modality in assessing
soft tissue knee pathology. One of the main issues with
the use of MRI is the rate of false positive (FP) and false
negative (FN) ﬁndings,1,2 which may result in unnec-
essary arthroscopic surgeries (for FPs) or in the delay of
therapies (for FNs) for pain relief.
Arthroscopy is the gold standard against which
other imaging technologies are compared.3 However,
arthroscopy is rarely used as a diagnostic tool and has been
replaced by MRI.4
Recently introduced, needle arthroscopy (NA) has
demonstrated equivalent accuracy to standard arthros-
copies in the diagnosis of meniscal5,6 and femoral
condylar lesions.5 Some of the advantages in using NA
in the physician’s ofﬁce are convenience and imme-
diacy of diagnosis as it can be performed as part of an
initial patient visit.7
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The purpose of this analysis is to determine
whether NA compared with MRI in the diagnosis and
treatment of meniscal tears is cost-effective when
evaluated over a 2-year period via patient-reported
outcomes. The hypothesis is that improved diag-
nostic accuracy with NA would lead to less costly care
and similar outcomes.
Methods
Literature searches were performed on November 9
and 10, 2017, using the following search terms in
PubMed: ((((Quality) AND Life) AND Instruments)
AND arthroscopy) AND knee (11 articles identiﬁed; 2
articles obtained); PubMed: (((MRI) AND knee) AND
quality) AND life (95 articles identiﬁed; 6 articles
Table 1. Sensitivities/Speciﬁcities (%) Used in the Markov
Model
Condition Needle Arthroscopy
Magnetic
Resonance Imaging
Medial meniscus 95/975 90/8114
Lateral meniscus 93/905 75/9414
Fig 1. Decision tree comparing use of needle arthroscopy to magnetic resonance imaging as a diagnostic prior to surgery.
COST-EFFECTIVENESS OF NEEDLE KNEE ARTHROSCOPY 555
obtained); PubMed: (((knee) AND arthroscopy) AND
cost) AND effectiveness (62 articles identiﬁed; 4 arti-
cles obtained); EBSCO: Quality of Life AND knee AND
arthroscopy (100 articles identiﬁed; 4 articles
obtained).
The base case population evaluated middle-age (mid
to late 40s to the early 50s) adults with intra-articular
knee damage (medial and/or lateral meniscal damage)
presenting with symptoms indicative of a meniscal
lesion, who were not contraindicated to completing an
MRI, who did not have an infection, and who presented
to an orthopaedic physician specializing in arthroscopy
with knee pain for several months. Based on clinical
work-up, an MRI versus in-ofﬁce diagnostic NA was
indicated. A decision to treat or not was made on the
MRI or NA diagnosis.
Modeling the Condition
TreeAge Pro 2017 Markov modeling software was
used to evaluate the cost and effectiveness of NA versus
MRI in the diagnoses and subsequent treatment based
on the ﬁndings of both diagnostic modalities based on
results in the medical literature. TreeAge Pro is a deci-
sion support model accepted by such organizations as
the National Institutes for Health and Clinical Excel-
lence (United Kingdom).8
Diagnoses and Treatment(s)
The following diagnoses were evaluated: medial
and lateral meniscus pathology. Treatment for each
condition occurred for true positive (TP) and FP for both
NA and MRI ﬁndings. For meniscus pathology it was
assumed that a partial meniscectomy (medial or lateral;
CPT 29881) was performed in symptomatic patients
without severe degenerative knee pathology and that
subsequent follow-up care provided including physical
therapy. The reason a partial meniscectomy was chosen
was for simplicity’s sake and owing to the fact that it is the
dominant procedure performed. True negative (TN)
ﬁndingswere not treated, and it was assumed the patient
hadno follow-up clinical care. FNﬁndingswere followed
up with physical therapy ﬁrst and, if this failed, hyal-
uronic acid (HA) injections were administered.9-11 HA
was administered if patients were in pain or had
degenerative disease (e.g., early-stage osteoarthritis); HA
treatments are found to be the safest and longest lasting
for lowering the pain.12 This treatment paradigm
attempted to follow current practice patterns, coverage
policies of the major private payers, and appropriate use
criteria.13 If these failed, patients went on to surgery
(CPT 29881). The sensitivities and speciﬁcities used in
the Markov model are found in Table 1.
Inputs
Evaluation of Outcomes
Outcomes for patients undergoing therapy (or not)
for suspected knee damage were evaluated for effec-
tiveness using the knee injury and osteoarthritis
outcome score (KOOS). KOOS is an instrument mainly
used for evaluating osteoarthritis but has also been
validated for knee injury.15 KOOS4 (mean score for
four of ﬁve KOOS subscale scores: pain, other symp-
toms, function in sport and recreation, and knee related
quality of life) was used in the model to evaluate the
various outcome states the patient exhibited over a 2-
year period from baseline. KOOS scores at each time
frame were then totaled for an aggregate outcome
score. Appendix Table 1 shows the relevant KOOS4
values used in the Markov model at baseline and 1 and
2 years. Outcomes were discounted at 3%.16
Evaluation of Costs
The direct costs for diagnosis and treatment were
based on the 2017 Medicare national average fee
Fig 2. Transition state diagram of a false positive magnetic
resonance imaging ﬁnding and resultant care based on that
ﬁnding.
Table 2. Medicare
Condition NA (Costs/KOOS4) Magnetic Resonance Imaging (Costs/KOOS4) Cost Savings With NA Cost-Effectiveness
Medial meniscus 3,996/187 4,776/185 780 NA dominant
Lateral meniscus 2,324/206 2,638/201 314 NA dominant
NOTE. All costs are in dollars.
KOOS, knee injury and osteoarthritis outcome score; NA, needle arthroscopy.
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schedule and are found in Appendix Table 1. MRI and
NA private payer reimbursement rates were based on
available data.17 Private payment rates were based on
an assumed premium of 30% over Medicare rates.
Surgical procedures were assumed to take place in the
hospital outpatient setting. MRI was assumed to take
place in the hospital outpatient setting as well (CPT
73721 þ APC 5523; $240 þ $219 ¼ $459 for Medi-
care18 and $1,628 for private pay17) or in a freestanding
MRI facility (private pay at $1,050).7 NA was assumed
to take place in the physician ofﬁce setting and was
reimbursed using CPT 29870 ($598 for Medicare18 and
$958 for private pay [Data on ﬁle: VisionScope Tech-
nologies]). The costs of performing CPT 29870 in the
physician ofﬁce setting are included in CPT 29870 and
reﬂect such expenses as needle arthroscope, cost of the
dressing/injection/anesthetic, cost of administration
and preparation of the medication and the room
(practice expenses), and the time to perform the pro-
cedure (physician work). All of these costs are
embedded in the relative value units for both physician
work and practice expense.19 Additionally, it was
assumed that the patient population would represent a
typical enrollee of either private insurer or Medicare.
Complications were also factored into surgical proced-
ures and included deep vein thrombosis, pulmonary
embolism, venous thromboembolism, and any other
complication requiring a patient be admitted to the
hospital. These costs and their incidence were derived
from the medical literature.20,21 Costs were discounted
at 3%.16
Running the Model
Based on the probability of a ﬁnding of a TP or FP,
patients were surgically treated and corresponding
health states were assumed postprocedure relating to
complications, rehabilitation, and outcome. For FN
ﬁndings, it was assumed patient ﬁrst underwent phys-
ical rehabilitation. If this failed, patients underwent HA
injections, and if those failed, they ultimately under-
went surgery9-11,22,23 Figure 1 shows the Markov
model for diagnosis and treatment for the medial
meniscus. Figure 2 shows the structure for Markov state
transition diagram for an FP ﬁnding. One- and 2-way
sensitivity analyses were performed to determine
which variables had the greatest effect on overall cost
for care. Each variable was varied at least 25% to
determine strength of the ﬁndings and to determine the
point at which MRI or NA was the preferred diagnostic
based on overall costs. Incremental cost effect scatter-
plot analysis using Monte Carlo simulation (sampling
probabilistic sensitivity, run 10,000 times) was per-
formed to determine the percentage of time therapies
that were dominant (resulted in overall lower cost with
improved outcomes) for each condition. All probabili-
ties of events occurring are identiﬁed in Appendix
Table 1 for medial meniscus pathology. Four different
Markov models were developed: medial and lateral
meniscus (using Medicare or private pay information)
with appropriate therapeutic follow-up. These models
differed slightly based on speciﬁcities and sensitivities
for MRI and NA (as per Table 1) and for surgical ther-
apy for meniscal damage as well.
Last, the consolidated economics evaluation and
reporting standards checklist24 was used to ensure
recommended items were included in the economic
evaluation (Appendix Figure 1).
Results
Baseline 2-year costs and outcomes derived from
each Markov model for Medicare and for private pay
are shown in Tables 2 and 3.
Appendix Table 2 shows each of the stages (years 0 to
2; with “0” being the initial encounter/procedure) and
state transitions for NA and MRI for TP, FP, TN, and FN
ﬁndings. Each of these stages has an associated proba-
bility of occurring, an associated cost, and outcome as
measured by KOOS4. The values identiﬁed in Appendix
Table 2 are for a medial meniscus tear using Medicare
costs. Furthermore, each of the TPs, FPs, TNs, and FNs
also has an associated probability of occurring based on
the literature.15,25
The incremental cost-effectiveness (ICE) scatterplots
in Monte Carlo simulation with respect to NA versus
MRI dominance using Medicare data are summarized
Table 4. Medicare Data
Condition
Needle
Arthroscopy
Dominant %
of Time
Magnetic
Resonance
Imaging
Dominant %
of Time
ICER Ratio
for NA
Medial meniscus 61 9 N/A
Lateral meniscus 80 5 N/A
ICER, incremental cost effectiveness ratio; N/A, not applicable.
Table 3. Private Payer Payment Rates
Condition NA (Costs/KOOS4) Magnetic Resonance Imaging (Costs/KOOS4) Cost Savings With NA Cost-Effectiveness
Medialmeniscus 5,361/187 7,223/185 1,862 NA dominant
Lateral meniscus 3,193/206 4,449/201 1,256 NA dominant
NOTE. All costs are in dollars.
KOOS, knee injury and osteoarthritis outcome score; NA, needle arthroscopy.
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in Table 4 and in Figure 3 (used as an example of an ICE
scatterplot). ICE scatterplots in Monte Carlo simulation
showed that with private pay rates, NA was dominant
to MRI the majority of the time (Table 5). Two-way
sensitivity analysis demonstrated that at various costs
for both MRI and NA, NA was the less costly alternative
in the majority of cases (Table 6). One-way sensitivity
demonstrated that the following variables and thresh-
olds affected the model, resulting in a lower cost for
MRI versus NA based on Medicare payment amounts
(Table 7) and private pay payment amounts (Table 8):
cost of NA, cost of MRI, percentage of MRI positives,
and percentage of NA positives. Note that all parame-
ters/ranges used can be found in Appendix Table 1 for
Medicare (medial meniscus only) and Appendix Table 3
for private pay (medial meniscus only).
Discussion
In analyzing the cost-effectiveness of NA using Mar-
kov modeling, NA was found to be less costly than MRI
while providing for “equivalent/improved” outcomes.
With private payers, MRI reimbursement for the lower
limb without contrast, from a recent analysis surveying
1,584 hospitals (and from 3 large private insurers:
Aetna, Humana, and United Healthcare), averaged
$1,332  509 (2011 data, inﬂated to 2017 using hos-
pital outpatient medical CPI $1,628  $622).17 In
contrast, internal data collected on CPT 29870 (diag-
nostic knee arthroscopy; physician ofﬁce setting) for
private payers (Aetna, BCBS, CIGNA, Humana, United
Healthcare mainly in the following states: CA, CT, GA,
IL, NJ, MA) estimated a reimbursement rate of $958 
$317 (data available from VisionScope Technologies
and consistent with Truven data, $1,175). When using
these values in the models, NA dominated MRI.
For this analysis, it was assumed that an MRI for a
private pay patient would be performed in the hospital
outpatient setting, where reimbursement is highest,
$1,628. This is compared with an approximate $1,050
reimbursement rate for an MRI performed in a free-
standing MRI facility.7 If the MRI value of $1,050 were
used in the analysis, NA still would be the least costly in
all lesions examined with savings of $1,284 (medial
meniscus) and $678 (lateral meniscus). In other words,
no matter the setting for an MRI under private pay, NA
Quadrant III: NA
IC>0; IE< 0;24%
Quadrant II: NA
IC>0; IE<0.   (MRI
dominant 11% of
time) Quadrant I: NA
IC>0;  IE>0;  2% 
Quadrant IV:  NA
IC<0;  IE>0  (NA
dominant 63% of
time)
Fig 3. Medial meniscus Medicare incremental cost-effectiveness scatterplot examining the probabilities of incrementally lower or
higher costs and knee injury and osteoarthritis outcome scores in using needle arthroscopy versus magnetic resonance imaging.
Table 5. Private Payer Data
Condition
Needle
Arthroscopy
Dominant %
of Time
Magnetic
Resonance
Imaging
Dominant %
of Time
ICER Ratio
for NA
Medial meniscus 64 2.8 N/A
Lateral meniscus 86 1.2 N/A
ICER, incremental cost effectiveness ratio; N/A, not applicable.
Table 6. Two-Way Sensitivity
Condition Difference in Cost for MRI to Be Preferred
Medial meniscus NA >$919 more costly than MRI ($1,378 less
$459); NA is the less costly alternative.
Lateral meniscus NA >$453 more costly than MRI ($912 less
$459); NA is the less costly alternative.
MRI, magnetic resonance imaging; NA, needle arthroscopy.
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was the least costly alternative and provided for
“equivalent/improved” outcomes. Although the reim-
bursement rate for MRI and NA may vary across the
United States based on negotiated rates between pro-
viders and insurers, the private pay reimbursement
rates for NA and MRI in this analysis were derived from
large data sets and from large payers (Data on ﬁle:
VisionScope Technologies; Truven 2017 data). In a
separate sensitivity analysis of the cost of an MRI
(Table 8), the following MRI private pay re-
imbursements would need to be met for MRI to be the
less costly alternative: for the medial meniscus, NA is
always the less costly alternative no matter the MRI
reimbursement (ranges evaluated in sensitivity analysis
$0 to $3,000); for the lateral meniscus, MRI would need
to be <$371 (Fig 4).
In all clinical scenarios, NA produced superior out-
comes versus MRI as measured by KOOS4. The KOOS4
scores as evaluated in this analysis assumed a given
treatment paradigm (e.g., all FPs were treated with
surgical arthroscopy, and all FNs were treated via sur-
gical arthroscopy if PT and HA injections were ﬁrst not
successful), which may not be the case in actual prac-
tice. Speciﬁcally, some clinicians may not treat FP
ﬁndings and FN ﬁndings may not deteriorate to the
point of requiring an intervention. Thus, the KOOS4
outcomes ﬁndings herein may be subject to debate.
Gill et al.5 published the accuracies (sensitivities and
speciﬁcities) used in the model. These accuracies were
in line with other studies.6,26 It should also be noted
that in the Gill et al.5 study, the kappa statistics
comparing NA with surgical diagnostic arthroscopy
(standard bore size arthroscope) were very high, indi-
cating no signiﬁcant difference between the 2
modalities.
In 1-way sensitivity analysis, MRI has always been
more sensitive in medial versus lateral pathology.27
Thus, the overall positive ﬁnding threshold (TP þ FP)
for preferring MRI to NA is higher with medial versus
lateral pathology (Tables 7 and 8). The lateral meniscus
presents challenges based on the oblique orientation of
the posterior horn with its sloping upward course at its
attachment and small radial curvature. This makes tears
of the posterior horn and tears involving less than one-
third of the lateral meniscus difﬁcult to identify on
MRI.28,29 This lower sensitivity has also not improved,
despite improvements in magnet technology.6 It was
also independent of the duration of the tear.28 Based on
inconclusive data presented from MRI, the vast ma-
jority of these tears tend to be ultimately be treated
surgically.29 In these cases, it is likely that the initial use
of NA (vs MRI) would have resulted in a more timely
treatment of the tear, perhaps with less patient pain
over time.
From clinical practice, health policy, and patient
satisfaction standpoints, NA may present advantages.
NA is a diagnostic procedure that can be performed
with the patient awake in a physician’s ofﬁce setting. A
diagnosis can then be made by the clinician at that
point, with 1 encounter establishing deﬁnitive diagnosis
and treatment.
Further, considering there can be a signiﬁcant num-
ber of patients who are missed with MRI (i.e., FN
ﬁndings) for the lateral meniscus pathology,5,14 inap-
propriate care may be delivered. Additionally, based on
the relatively high incidence of FP ﬁndings in medial
meniscus pathology, there is the potential for unnec-
essary surgical treatment. There has been a push
recently by policy makers and the medical community
to ensure appropriate care is being delivered in all care
settings, including emphasizing individual patient needs
as the top priority.30 Thus, NA may be an alternative for
delivering more appropriate care.
The current analysis differs from a prior analysis that
focused on Medicare costs only and was examined over
the acute phase of care.31 This analysis includes private
Table 7. One-Way Sensitivity Analysis of Variables that Most
Affected the Markov Model (Medicare)
Variable (also Appendix Table 1)
Medial
Meniscus
Lateral
Meniscus
Cost of NA (CPT 29870) ¼ $598 >1,378 >912
Percentage of MRIs positive of MRIs
performed (positive þ negative
ﬁndings)
<43 <21
Percentage of NAs positive of all NAs
performed (positive þ negative
ﬁndings)
>54 >24
NOTE. Values above or below those shown resulted in either NA or
MRI being the more costly option.
MRI, magnetic resonance imaging; NA, needle arthroscopy.
Table 8. One-Way Sensitivity Analysis of Variables that Most
Affected the Markov Model (Private Pay)
Variable
(also Appendix Table 3)
Medial
Meniscus
Lateral
Meniscus
Cost ($) of MRI (CPT 73721)
(model assumes cost of
$1,628  $622 [facility]
and $1,050 [nonfacility]
MRI always
more expensive
<371
Cost ($) of NA (CPT 29870)
(model assumes cost
of $958  $317)
>2,820 >2,215
Percentage of MRIs positive
of MRIs performed
(positive þ negative ﬁndings)
<35 <11
Percentage of NAs positive
of all NAs performed
(positive þ negative ﬁndings)
>63 >33
NOTE. Values above or below those shown resulted in either NA or
MRI being the more costly option.
MRI, magnetic resonance imaging; NA, needle arthroscopy.
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pay reimbursement and outcomes (KOOS4) and
examines a patient over a 2-year period. This study also
adds further clarity to the effect of NA on private
insurers, where the majority of this type of condition is
evaluated and treated.
Limitations
Indirect costs were not factored into this analysis.
These costs include time absent from work, loss of
productivity (owing to pain), out-of-pocket expenses
related to transportation, travel time, assistive devices,
and time spent on follow-up.32,33
MRI results that were obtained from the literature
were derived from academic medical centers where
more advanced MRI technology (i.e., higher resolution
of intra-articular disease) is available and generally
where more experienced musculoskeletal radiologists
reside.34 MRI results from community practices have
demonstrated lower accuracy.11
KOOS4 was used as a proxy for outcome. This was a
global score using 4 of the 5 subscale scores for patient
with meniscal tears and osteoarthritis (pain, other
symptoms, function in sports and recreation, and knee
quality of life). The KOOS4 data were derived from a
randomized controlled trial recently completed in
middle-age patients (which was the population for this
cost-effectiveness evaluation).35
It was assumed that all patients in the analysis would
be willing to undergo NA in the ofﬁce. This may not be
the case, and there may crossover to MRI assessment
owing to its noninvasive nature. This crossover was not
accounted for in the analysis.
It was assumed that symptomatic patients with TP
and FP (with diagnosed pathologydeither MRI or NA)
were treated arthroscopically for a meniscectomy. This
was based on an evidence-based review of meniscal
tears after surgery with short-term satisfactory results
occurring in approximately 90% of patients.36 In other
words, there is a high likelihood that patients will
beneﬁt from a surgical intervention. Additionally, with
respect to FP MRI ﬁndings and our assumption that FP
went on to surgery, Medicare CPT historical use data for
the years 2000 to 2015 have shown a consistency of use
for codes 29870 (diagnostic knee arthroscopy) and CPT
29880 plus 29881. CPT codes 29880/29881 have made
up 73% to 75% of all surgical knee arthroscopies over
this time frame.37 CPT 29870 has also made up 1.2% to
1.3% of the 29880/29881 total. Since FPs in MRI are in
the 10% to 15% range, the historical use of CPT 29870
should be much higher. It is therefore the assumption
that FP MRI results are being treated surgically in
everyday practice.
The negative predictive value of MRI and NA has
been shown to be quite high in meniscal tears,5,38 and
unless the patient had clinical symptoms indicative of a
meniscal tear (along with a negative MRI and NA),
follow-on arthroscopy was not performed. Since this
occurs infrequently, surgery was not accounted for in
TN ﬁndings.
It was assumed patients were treated conservatively
at ﬁrst based on an FN ﬁnding. This was based on the
standards of care for treating pain.39-41 Ultimately if the
patient outcome did not improve, that patient under-
went a surgical arthroscopic procedure.
The use of MRI in patients with suspected bony edema
(and with joint effusion) may be the more appropriate
diagnostic modality versus NA because a differential
diagnosis can be obtained. In patients with acute trauma
with joint effusion,MRI can provide additional diagnostic
capabilities regarding the condition of subchondral bone
Fig 4. Sensitivity analysis of cost of magnetic resonance imaging (private pay rate) in evaluating a lateral meniscus lesion.
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and alternative treatment(s).42 This was not evaluated in
this analysis and is a limitation of the data evaluated.
Last, the cost analysis covers 2 years only. Therefore,
the ﬁndings of cost savings should be restricted to this
time frame.
Conclusions
Based on the reported MRI incidence of FPs with the
medial meniscus and FNs with the lateral meniscus
based on assumed standards of care, more costly care is
provided when using MRI compared with NA. Out-
comes were similar with NA compared with MRI.
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Appendix Table 1. Variables and Distributions Used in the Markov Model for Medicare
Variables Used in the Model: Medial Meniscus Assessment/Treatment
Name Description Formula Value Low High Comment
Anesthesia_outpatient_meniscectomy CPT 01400: anesthesia for a
30-minute arthroscopic
meniscectomy hospital
outpatient setting
$132 $132 $0 $132 Base units ¼ 4; 1 unit each for
15 minutes of patient being under;
total of 6 units. CMS 2017 CF ¼
$22.05. Therefore, 6 units  $22.05 ¼
$132.30
APC_arthroscopic_meniscectomy APC 5113: facility payment for
surgical meniscectomy
$2,425 $2,425 $0 $2,425 APC 5113: for use with CPT 29881.
Medicare 2017 fee schedule.
Corticosteroid_injection CPT 20610: arthrocentesis and/or
corticosteroid injection
$62 $62 $0 $62 Medicare 2017 national average
payment amount for arthrocentesis
and/or corticosteroid injection.
Cost_DVT Cost to treat a DVT over a
12-month period
$16,322 $16,322 $0 $0 Source: Spyropoulos AC, Lin J. Direct
medical costs of VTE and subsequent
hospital readmission rates: An
administrative claims analysis form 30
managed care organizations. J Manag
Care Pharma 2007;13:475-486. Costs
inﬂated using medical CPT from 2007
to 2017.
Cost_orthopedic_readmit_comp Cost orthopedic readmit owing to
comp: DRG 565
$6,623 $6,623 $0 $12,000 Medicare 2017 national average
payment for DRG 565: OTHER
MUSCULOSKELETAL SYS &
CONNECTIVE TISSUE DIAGNOSES W
CC
Cost_PE Cost to treat a PE over a 12-month
period
$25,144 $25,144 $0 $40,000 Source: Spyropoulos AC, et al. (2007).
Costs inﬂated using medical CPT from
2007 to 2017.
Cost_VTE Cost to treat a VTE over a
12-month period
Cost_complication_VTE $25,730 $0 $40,000 Source: Lin J, Lingohr-Smith M, Kowng
WJ. Incremental health care resource
utilization and economic burden of
venous thromboembolism recurrence
from a US payer perspective. Jrl Manag
Care Pharm 2014;20:174-186.
Cost_Wound_comp_
arthroscopic_lavage_drainage
CPT 29871: arthroscopic lavage
and drainage for infection +
APC 5113
$2,956 $2,956 $0 $5,000 Medicare 2017 national average
payment rate for arthroscopic lavage
and drainage: infection plus APC 5113
at $2,425.
CPT_arthroscopic_meniscectomy CPT 29881: partial meniscectomy,
medial or lateral
$558 $558 $0 $1,000 Medicare 2017 national average
payment amount for a meniscectomy
of the knee: medial or lateral; facility
setting.
CPT_diagnostic_
arthroscopy_knee_Medicare
CPT 29870: diagnostic knee
arthroscopy physician ofﬁce,
Medicare
$598 $598 $0 $1,500 Medicare 2017 national average
payment amount for a diagnostic knee
arthroscopy: physician ofﬁce setting.
(continued)
Appendix
C
O
ST
-E
F
F
E
C
T
IV
E
N
E
SS
O
F
N
E
E
D
L
E
K
N
E
E
A
R
T
H
R
O
SC
O
P
Y
5
6
2
.e1
Appendix Table 1. Continued
Variables Used in the Model: Medial Meniscus Assessment/Treatment
Name Description Formula Value Low High Comment
CPT_diagnostic_arthroscopy_knee_PP CPT 29870: diagnostic knee
arthroscopy physician ofﬁce,
private pay
$958 $958 $0 $3,000 Average private payer rates for NA
obtained from explanation of beneﬁts
for various payers, including Blue
Cross Blue Shield, Aetna, United,
CIGNA, Harvard Pilgrim Health Plan.
Mean  SD ¼ $958  $317.
CPT_Evaluation_Mgmt_Existing CPT code for a follow-up
evaluation and management on
an existing patient
$109 $109 $0 $200 Medicare 2017 national average
payment amount for a 30-minute
physical examination: existing patient.
CPT_Evaluation_Mgmt_existing_injection Cost E&M for injection
corticosteroid: CPT 99212
$44 $44 $0 $100 Medicare 2017 national average
payment rate: CPT 99212.
CPT_Evaluation_Mgmt_New CPT code for evaluation and
management: patient history
and examination
$166 $166 $0 $300 Medicare 2017 national average
payment amount for a 30-minute
physical examination: new patient.
CPT_MRI_knee_Medicare CPT 73721: MRI knee without
contrast, Medicare
$240 $240 $0 $1,500 Medicare 2017 national average
payment amount for an MRI of the
knee without contrast.
CPT_MRI_Knee_PP CPT 73721: MRI knee without
contrast, private pay
$1,628 $1,628 $0 $3,000 Cooper Z, Craig SV, Gaynor M, Van
Reenen J. The price ain’t right?
Hospital prices and health spending on
the privately insured. Working paper
21815. National Bureau of Economic
Research. Published December 2015.
Revised May 2018. The 2011
reimbursement rates are inﬂated to
2017.
CPT_Xray_knee CPT 73564 x-ray knee: 4 views $40 $40 $0 $80 Medicare 2017 national average
payment amount for x-rays of the
knee: 4 views.
KOOS4_baseline_score KOOS4_baseline 56.95 0 85 Source: Kise NJ, Risberg MA, Stensrud S,
Ranstam J, Engebretsen L, Roos EM.
Exercise therapy versus arthroscopic
partial meniscectomy for degenerative
meniscal tear in middle aged patients:
randomised controlled trial with two
year follow-up. BMJ 2016;354:i3740.
KOOS4_one_year_exercise KOOS4_excercise_one_year 82.53 0 90 Source: Kise NJ, et al. (2016).
KOOS4_one_year_meniscectomy KOOS4_meniscectomy_one_year 86.93 0 95 Source: Kise NJ, et al. (2016).
KOOS4_two_year_exercise KOOS4_exercise_two_years 88.2 0 95 Source: Kise NJ, et al. (2016).
KOOS4_two_year_meniscectomy KOOS4_meniscectomy_two_years 87.4 0 95 Source: Kise NJ, et al. (2016).
MRI_positives MRI positive ﬁndings out of all
ﬁndings (positive + negative)
Positive_ﬁndings_MRI 55% 0% 99% Crawford R, Walley G, Bridgman S,
Mafulli N. Magnetic resonance
imaging versus arthroscopy in the
diagnosis of knee pathology,
concentrating on meniscal lesions and
ACL tears: A systematic review. Br Med
Bull 2007;84:5-23.
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Appendix Table 1. Continued
Variables Used in the Model: Medial Meniscus Assessment/Treatment
Name Description Formula Value Low High Comment
NA_positives Needle arthroscopy positive
ﬁndings out of all NA ﬁndings
(positive + negative)
Positive_ﬁndings_NA 43% 0% 99% Based on VisionScope NA ﬁndings. Data
on ﬁle.
Physical_therapy_cost_week Cost physical therapy per week $660 $660 $0 $15,000 CPT 97110 pays at $33 per 15-minute
session. Assume 4 sessions per day;
5 days per week. Therefore, $33  4 
5 ¼ $660 per week.
Physical_therapy_initial_evaluation CPT 97162: initial evaluation for
physical therapy
$83 $83 $0 $150 Medicare 2017 national average
payment for CPT 97162: initial
evaluation for physical therapy.
Physical_therapy_knee Physical therapy knee: assume
3-6 weeks
Physical_therapy
_duration_post_surg
4.5 0 9 Assumed course of physical therapy
based on coverage determinations of
Medicare and private payers.
Probability_comp_DVT Probability DVT meniscal surgical
arthroscopic procedure
0.12% 0.12% 0% 1% Source: Jameson SS, Dowen D, James P,
Serrano-Pedraza I, Reed MR, Deehan
DJ. The burden of arthroscopy of the
knee: a contemporary analysis of data
from the English NHS. J Bone Joint Surg
Br 2011;93:1327-1333.
Probability_comp_PE Probability PE meniscal surgical
arthroscopic procedure
0.08% 0.08% 0% 0.2% Source: Jameson SS, et al. (2011).
Probability_comp_readmit Probability readmit owing to
meniscal surgical arthroscopic
procedure
0.45% 0.45% 0% 1% Source: Jameson SS, et al. (2011).
Probability_comp_VTE Probability VTE meniscal
arthroscopic surgical procedure
0.19% 0.19% 0% 0.5% Source: Jameson SS, et al. (2011).
Probability_comp_wound Probability wound complication
meniscal arthroscopic surgical
procedure
0.11% 0.11% 0% 0.5% Source: Jameson SS, et al. (2011).
Probability_complication Probability complication post
knee surgery
Probability_complication
_knee_arthroscopy
1% 0% 2% Weighted average cost of DVT, PE, VTE,
readmit, wound complication based on
the probabilities of occurrence and
over a 12-month time frame. Derived
from the medical literature and
inﬂated to 2017.
Probability_pain_meds_success Probability corticosteroid
injections relived pain
symptoms
50% 50% 0% 90% Estimated.
Probability_rehab_post_med_failure Probability exercise rehabilitation
post medication failure
85% 85% 0% 95% Source: Cavanaugh JT, Killian SE.
Rehabilitation following meniscal
repair. Curr Rev Musculoskelet Med
2012;5:46-58.
Probability_rehab_success Probability rehab success post
meniscectomy
Probability_meniscal
_repair_success
80% 0% 90% Source: Cavanaugh JT, et al. (2012)
TN_MRI True_negatives_MRI 90% 0% 95% Crawford R, et al. (2007).
TN_NA True_Negatives_NA 86% 0% 99% Based on VisionScope NA ﬁndings. Data
on ﬁle.
TP_MRI True_positives_MRI 83% 0% 95% Crawford R, et al. (2007).
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Appendix Table 1. Continued
Variables Used in the Model: Medial Meniscus Assessment/Treatment
Name Description Formula Value Low High Comment
TP_NA True_positives_NA 97% 0% 99% Based on VisionScope NA ﬁndings. Data
on ﬁle.
Weighted_average_complication_cost Weighted_average_cost_complication $12,804 $0 $20,000 Weighted average cost of DVT, PE, VTE,
readmit, wound complication based on
the probabilities of occurrence and
over a 12-month time frame. Derived
from the medical literature and
inﬂated to 2017.
Distributions Used in the Model
Description Type Parameters EV Comment
Physical therapy in weeks after arthroscopic
meniscal surgery
Uniform Subtype: 2, low: 3, high: 6 4.5 Assumed course of physical therapy based on
coverage determinations of Medicare and private
payers.
Cost of treating a VTE over a 12-month period,
Medicare
Normal Mean: 25730; SD: 40,250 $25,730 Source: Lin J, et al. (2014).
Weighted average cost of a complication post
arthroscopy
Normal Mean: 12804; SD: 10,000 $12,804 Weighted average cost of DVT, PE, VTE, readmit,
wound complication based on the probabilities of
occurrence and over a 12-month time frame.
Derived from the medical literature and inﬂated
to 2017.
Percentage of positive ﬁndings on MRI vs total
ﬁndings
Uniform Subtype: 2; low: 0.4; high: 0.7 55% Assumed positive ﬁndings for medial meniscus
pathology for MRI.
Percentage of TNs of all negative ﬁndings MRI (TN
+ FN)
Uniform Subtype: 2; low: 0.85; high: 0.95 90% Assumed negative ﬁndings for medial meniscus
pathology for MRI.
KOOS4 at 2-year exercise group Triangular Min: 81.1; likeliest: 85; max: 98.5 88.2 Source: Kise NJ, et al. (2016).
Probability of meniscus repair success post rehab Uniform Subtype: 2; low: 0.7; high: 0.9 80.0% Source: Cavanaugh JT, et al. (2012).
Percentage of positive ﬁndings of all ﬁndings NA
(TP + FP)
Uniform Subtype: 2; low: 0.4; high: 0.45 42.5% Based on VisionScope NA ﬁndings. Data on ﬁle.
Probability knee complication Triangular Min: 0.001; likeliest: 0.0095; max: 0.02 1.02% Probability of a complication based on all
complications summed up: 0.95%
Percentage of TN NA of all negatives (TN + FN) Triangular Min: 0.725; likeliest: 0.882; max: 0.967 85.8% Based on VisionScope NA ﬁndings. Data on ﬁle.
KOOS4 at 1-year exercise Triangular Min: 74.9; likeliest: 79.5; max: 93.2 82.53 Source: Kise NJ, et al. (2016).
Percentage of TPs of all positives (TP + FP) Triangular Min: 0.922; likeliest: 0.986; max: 1 96.9% Based on VisionScope NA ﬁndings. Data on ﬁle.
Percentage of TPs of all positive MRI ﬁndings (TP +
FP)
Uniform Subtype: 2; low: 0.8; high: 0.85 82.5% Crawford R, et al. (2007).
KOOS4 at 2-year meniscectomy Triangular Min: 80.4; likeliest: 84.1; max: 97.7 87.4 Source: Kise NJ, et al. (2016).
KOOS4 at 1-year meniscectomy Triangular Min: 79.9; likeliest: 83.7; max: 97.2 86.93 Source: Kise NJ, et al. (2016).
KOOS4 baseline score meniscus damage Normal Mean: 56.95; SD: 16.37 56.95 Source: Kise NJ, et al. (2016). Combined mean
from exercise and meniscectomy groups: N ¼ 70
both groups; mean  SD exercise: 54.3  18.2
and meniscectomy: 59.6  13.8.
APT, Ambulatory Payment Classiﬁcation; CPT, Current Procedure Terminology; DRG, Diagnosis Related Group; DVT, deep vein thrombosis; E&M, evaluation and management; EV, expected
value; FN, false negative; FP, false positive; KOOS, knee injury and osteoarthritis outcome score; MRI, magnetic resonance imaging; NA, needle arthroscopy; PE, pulmonary embolism; SD,
standard deviation; TN, true negative; TP, true positive; VTE, venous thromboembolism.
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Appendix Table 2. Medicare Costs Over 2-Year Time Frame by Diagnostic Modality and Subsequent Treatment
True Positive, Needle Arthroscopy, Medical Meniscus
Stage State Probability, % State Cost, $ Stage Cost, $ Total Cost, $ State Effect Stage Effect Total Effect
0 Surgical treatment 100.00 3,919 3,919 3,919 56.95 56.95 56.95
0 Rehabilitation 0.00 0 3,919 3,919 0.00 56.95 56.95
0 Pain meds/injections 0.00 0 3,919 3,919 0.00 56.95 56.95
0 Success 0.00 0 3,919 3,919 0.00 56.95 56.95
0 Complication 0.00 0 3,919 3,919 0.00 56.95 56.95
1 Surgical treatment 0.00 0 4,132 8,051 0.00 86.63 143.58
1 Rehabilitation 98.98 4,002 4,132 8,051 86.05 86.63 143.58
1 Pain meds/injections 0.00 0 4,132 8,051 0.00 86.63 143.58
1 Success 0.00 0 4,132 8,051 0.00 86.63 143.58
1 Complication 1.02 130 4,132 8,051 0.58 86.63 143.58
2 Surgical treatment 0.00 0 62 8,113 0.00 18.35 161.93
2 Rehabilitation 1.02 41 62 8,113 0.89 18.35 161.93
2 Pain meds/injections 19.810 21 62 8,113 17.46 18.35 161.93
2 Success 79.19 0 62 8,113 0.00 18.35 161.93
2 Complication 0.00 0 62 8,113 0.00 18.35 161.93
False Positive, Needle Arthroscopy, Medial Meniscus
Stage State Probability, % State Cost, $ Stage Cost, $ Total Cost, $ State Effect Stage Effect Total Effect
0 Surgical treatment 100.00 3,919 3,919 3,919 56.95 56.95 56.95
0 Rehabilitation 0.00 0 3,919 3,919 0.00 56.95 56.95
0 Pain meds/injections 0.00 0 3,919 3,919 0.00 56.95 56.95
0 Success 0.00 0 3,919 3,919 0.00 56.95 56.95
0 Complication 0.00 0 3,919 3,919 0.00 56.95 56.95
1 Surgical treatment 0.00 0 4,132 8,051 0.00 86.63 143.58
1 Rehabilitation 98.98 4,002 4,132 8,051 86.05 86.63 143.58
1 Pain meds/injections 0.00 0 4,132 8,051 0.00 86.63 143.58
1 Success 0.00 0 4,132 8,051 0.00 86.63 143.58
1 Complication 1.02 130 4,132 8,051 0.58 86.63 143.58
2 Surgical treatment 0.00 0 62 8,113 0.00 18.35 161.93
2 Rehabilitation 1.02 41 62 8,113 0.89 18.35 161.93
2 Pain meds/injections 19.810 21 62 8,113 17.46 18.35 161.93
2 Success 79.19 0 62 8,113 0.00 18.35 161.93
2 Complication 0.00 0 62 8,113 0.00 18.35 161.93
True Negative, Needle Arthroscopy, Medial Meniscus
Stage State Probability, % State Cost, $ Stage Cost, $ Total Cost, $ State Effect Stage Effect Total Effect
0 Negative ﬁnding 100.00 804 804 804 56.95 56.95 56.95
1 Negative ﬁnding 100.00 0 0 804 82.53 82.53 139.48
2 Negative ﬁnding 100.00 0 0 804 88.20 88.20 227.68
False Negative, Needle Arthroscopy, Medial Meniscus
Stage State Probability, % State Cost, $ Stage Cost, $ Total Cost, $ State Effective Stage Effective Total Effective
0 Rehabilitation 100.00 1,547 1,547 1,547 56.95 56.95 56.95
0 Sodium hyaluronate injections 0.00 0 1,547 1,547 0.00 56.95 56.95
0 Surgical treatment 0.00 0 1,547 1,547 0.00 56.95 56.95
0 Success 0.00 0 1,547 1,547 0.00 56.95 56.95
0 Complication 0.00 0 1,547 1,547 0.00 56.95 56.95
1 Rehabilitation 0.00 0 157 1,704 0.00 16.51 73.46
1 Sodium hyaluronate injections 20.00 157 157 1,704 16.51 16.51 73.46
1 Surgical treatment 0.00 0 157 1,704 0.00 16.51 73.46
1 Success 80.00 0 157 1,704 0.00 16.51 73.46
1 Complication 0.00 0 157 1,704 0.00 16.51 73.46
2 Rehabilitation 0.00 0 152 1,855 0.00 0.00 73.46
2 Sodium hyaluronate injections 0.00 0 152 1,855 0.00 0.00 73.46
2 Surgical treatment 4.87 152 152 1,855 0.00 0.00 73.46
2 Success 95.13 0 152 1,855 0.00 0.00 73.46
2 Complication 0.00 0 152 1,855 0.00 0.00 73.46
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True Positive, Magnetic Resonance Imaging, Medial Meniscus
Stage State Probability, % State Cost, $ Stage Cost, $ Total Cost, $ State Effect Stage Effective Total Effective
0 Surgical treatment 100.00 3,780 3,780 3,780 56.95 56.95 56.95
0 Rehabilitation 0.00 0 3,780 3,780 0.00 56.95 56.95
0 Pain meds/injections 0.00 0 3,780 3,780 0.00 56.95 56.95
0 Success 0.00 0 3,780 3,780 0.00 56.95 56.95
0 Complication 0.00 0 3,780 3,780 0.00 56.95 56.95
1 Surgical treatment 0.00 0 4,132 7,912 0.00 86.63 143.58
1 Rehabilitation 98.98 4,002 4,132 7,912 86.05 86.63 143.58
1 Pain meds/injections 0.00 0 4,132 7,912 0.00 86.63 143.58
1 Success 0.00 0 4,132 7,912 0.00 86.63 143.58
1 Complication 1.02 130 4,132 7,912 0.58 86.63 143.58
2 Surgical treatment 0.00 0 62 7,974 0.00 18.35 161.93
2 Rehabilitation 1.02 41 62 7,974 0.89 18.35 161.93
2 Pain meds/injections 19.810 21 62 7,974 17.46 18.35 161.93
2 Success 79.19 0 62 7,974 0.00 18.35 161.93
2 Complication 0.00 0 62 7,974 0.00 18.35 161.93
False Positive, Magnetic Resonance Imaging, Medial Meniscus
Stage State Probability, % State Cost, $ Stage Cost, $ Total Cost, $ State Effect Stage Effective Total Effect
0 Surgical treatment 100.00 3,780 3,780 3,780 56.95 56.95 56.95
0 Rehabilitation 0.00 0 3,780 3,780 0.00 56.95 56.95
0 Pain meds/injections 0.00 0 3,780 3,780 0.00 56.95 56.95
0 Success 0.00 0 3,780 3,780 0.00 56.95 56.95
0 Complication 0.00 0 3,780 3,780 0.00 56.95 56.95
1 Surgical treatment 0.00 0 4,132 7,912 0.00 86.63 143.58
1 Rehabilitation 98.98 4,002 4,132 7,912 86.05 86.63 143.58
1 Pain meds/injections 0.00 0 4,132 7,912 0.00 86.63 143.58
1 Success 0.00 0 4,132 7,912 0.00 86.63 143.58
1 Complication 1.02 130 4,132 7,912 0.58 86.63 143.58
2 Surgical treatment 0.00 0 62 7,974 0.00 18.35 161.93
2 Rehabilitation 1.02 41 62 7,974 0.89 18.35 161.93
2 Pain meds/injections 19.810 21 62 7,974 17.46 18.35 161.93
2 Success 79.19 0 62 7,974 0.00 18.35 161.93
2 Complication 0.00 0 62 7,974 0.00 18.35 161.93
True Negative, Magnetic Resonance Imaging, Medial Meniscus
Stage State Probability, % State Cost, $ Stage Cost, $ Total Cost, $ State Effect Stage Effect Total Effect
0 Negative 100.00 774 774 774 56.95 56.95 56.95
1 Negative 100.00 0 0 774 82.53 82.53 139.48
2 Negative 100.00 0 0 774 88.20 88.20 227.68
False Negative, Magnetic Resonance Imaging, Medial Meniscus
Stage State Probability, % State Cost, $ Stage Cost, $ Total Cost, $ State Effective Stage Effective Total Effective
0 Rehabilitation 100.00 1,408 1,408 1,408 56.95 56.95 56.95
0 Sodium hyaluronate injections 0.00 0 1,408 1,408 0.00 56.95 56.95
0 Surgical treatment 0.00 0 1,408 1,408 0.00 56.95 56.95
0 Success 0.00 0 1,408 1,408 0.00 56.95 56.95
0 Complication 0.00 0 1,408 1,408 0.00 56.95 56.95
1 Rehabilitation 0.00 0 157 1,565 0.00 16.51 73.46
1 Sodium hyaluronate injections 20.00 157 157 1,565 16.51 16.51 73.46
1 Surgical treatment 0.00 0 157 1,565 0.00 16.51 73.46
1 Success 80.00 0 157 1,565 0.00 16.51 73.46
1 Complication 0.00 0 157 1,565 0.00 16.51 73.46
2 Rehabilitation 0.00 0 152 1,716 0.00 0.00 73.46
2 Sodium hyaluronate injections 0.00 0 152 1,716 0.00 0.00 73.46
2 Surgical treatment 4.87 152 152 1,716 0.00 0.00 73.46
2 Success 95.13 0 152 1,716 0.00 0.00 73.46
2 Complication 0.00 0 152 1,716 0.00 0.00 73.46
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Appendix Table 3. Variables and Distributions Used in the Private Pay Model
Private Pay Variables
Name Description Formula Value Low High Comment
Anesthesia_outpatient_meniscectomy CPT 01400: anesthesia for a
30-minute arthroscopic
meniscectomy, hospital
outpatient setting
$180 $180 $0 $250 Base units ¼ 4; 1 unit each of 15 minutes
of patient being under; total of 6 units.
CMS 2017 CF ¼ $22.05. Therefore, 6
units  $22.05 ¼ $132.30. Assuming a
30% markup for private pay over
Medicare ¼ 132  1.3 ¼ 180.
APC_arthroscopic_meniscectomy APC 5113: facility payment for
surgical meniscectomy
$3,153 $3,153 $0 $4,000 APC 5113: for use with CPT 29881.
Assume 30% markup for private pay:
$2425  1.3 ¼ 3153.
Cost_HA_injection Use of Medicare J7323 Euﬂexxa
per dose ¼ $155
$155 $155 $0 $500 Derived from Medicare payment rate for
J7323 at $155.
CPT_arthroscopic_meniscectomy CPT 29881: partial meniscectomy,
medial or lateral
$725 $725 $0 $1,000 Medicare 2017 national average
payment amount for a meniscectomy
of the knee: medial or lateral; facility
setting. Assume 30% markup of
private pay over Medicare: $558  1.3
¼ $725.
CPT_diagnostic_arthroscopy_knee CPT 29870: diagnostic knee
arthroscopy, physician ofﬁce
NA_knee $958 $0 $3,000 Private payer national average payment
amount for a diagnostic knee
arthroscopy: physician ofﬁce setting.
Data on ﬁle VisionScope.
CPT_Evaluation_Mgmt_Existing CPT code for a follow-up
evaluation and management on
an existing patient
$142 $142 $0 $180 Medicare 2017 national average
payment amount for a 30-minute
physical examination: existing patient.
Assume 30% markup of private pay
over Medicare: $109  1.3 ¼ $142.
CPT_Evaluation_Mgmt
_existing_injection
Cost E&M for injection
corticosteroid: CPT 99212
$57 $57 $0 $100 Medicare 2017 national average
payment rate: CPT 99212. Assume
30% markup of private pay over
Medicare: $44  1.3 ¼ $57.
CPT_Evaluation_Mgmt_New CPT code for evaluation and
management: patient history
and examination
$216 $216 $0 $300 Medicare 2017 national average
payment amount for a 30-minute
physical examination: new patient.
Assume 30% markup of private pay
over Medicare: $166  1.3 ¼ $216.
CPT_MRI_knee CPT 73721: MRI knee without
contrast
MRI_knee $1,628 $0 $3,000 Private pay 2017 national average
payment amount for an MRI of the
knee without contrast: hospital setting.
Truveen data.
CPT_Xray_knee CPT 73564 x-ray knee: 4 views $52 $52 $0 $100 Medicare 2017 national average
payment amount for x-rays of the
knee: 4 views. Assume 30% markup
of private pay over Medicare rate: $40
 1.3 ¼ $52.
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Appendix Table 3. Continued
Private Pay Variables
Name Description Formula Value Low High Comment
HA_injection CPT 20610: arthrocentesis and/or
injection
$81 $81 $0 $160 Medicare 2017 national average
payment amount for arthrocentesis
and/or corticosteroid injection.
Assume 30% markup of private pay
over Medicare: 62  1.3 ¼ 81.
KOOS4_baseline_score KOOS4_baseline 56.95 0.00 80.00 Source: Kise NJ, Risberg MA, Stensrud S,
Ranstam J, Engebretsen L, Roos EM.
Exercise therapy versus arthroscopic
partial meniscectomy for degenerative
meniscal tear in middle aged patients:
randomised controlled trial with two
year follow-up. BMJ 2016;354:i3740.
KOOS4_one_year_exercise KOOS4_excercise_one_year 82.53 0.00 90.00 Source: Kise NJ, et al. (2016).
KOOS4_one_year_meniscectomy KOOS4_meniscectomy_one_year 86.93 0.00 95.00 Source: Kise NJ, et al. (2016).
KOOS4_two_year_exercise KOOS4_exercise_two_years 88.20 0.00 95.00 Source: Kise NJ, et al. (2016).
KOOS4_two_year_meniscectomy KOOS4_meniscectomy_two_years 87.40 0.00 95.00 Source: Kise NJ, et al. (2016).
MRI_positives MRI positive ﬁndings out of all
ﬁndings (positive + negative)
Positive_ﬁndings_MRI 55.0% 0.0% 99.0% Crawford R, Walley G, Bridgman S,
Mafulli N. Magnetic resonance
imaging versus arthroscopy in the
diagnosis of knee pathology,
concentrating on meniscal lesions and
ACL tears: A systematic review. Br Med
Bull 2007;84:5-23.
NA_positives Needle arthroscopy positive
ﬁndings out of all NA ﬁndings
(positive + negative)
Positive_ﬁndings_NA 42.5% 0.0% 99.0% Based on VisionScope NA ﬁndings.
Source: Gill TJ, Safran M,
Mandelbaum B, Huber B, Gambardella
R, Xerogeanes J. A prospective,
blinded, multicenter clinical trial to
compare the efﬁcacy, accuracy, and
safety of in-ofﬁce diagnostic
arthroscopy with magnetic resonance
imaging and surgical arthroscopy.
Arthroscopy 2018;34:2429-2435.
Physical_therapy_cost_week Cost of physical therapy per week 858 $858 $0 $1,500 CPT 97110 pays at $33 per 15-minute
session. Assume 4 sessions per day;
5 days per week. Therefore, $33  4 
5 ¼ $660 per week. Assume 30%
markup of private pay over Medicare:
$660  1.3 ¼ $858.
Physical_therapy
_initial_evaluation
CPT 97162: initial evaluation for
physical therapy
108 $108 $0 $200 Medicare 2017 national average
payment for CPT 97162: initial
evaluation for physical therapy.
Assume 30% markup of private payer
over Medicare: $83  1.3 ¼ $108.
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Appendix Table 3. Continued
Private Pay Variables
Name Description Formula Value Low High Comment
Probability_complication Probability complication post
knee surgery
Probability_complication
_knee_arthroscopy
1.0% 0.0% 10.0% Weighted average cost of DVT, PE, VTE,
readmit, wound complication based on
the probabilities of occurrence and
over a 12-month timeframe. Derived
from the medical literature and
inﬂated to 2017.
Probability_HA_success Probability that HA is successful
in relieving pain
HA_effectiveness 75.7% 0.0% 90.0% Source: Concoff A, Sancheti P, Niazi F,
Shaw P, Rosen J. The efﬁcacy of
multiple versus single hyaluronic acid
injections: A systematic review and
meta-analysis. BMC Musculoskel Disord
2017;18(1):542.
Probability_pain_meds_success Probability corticosteroid
injections relieved pain
symptoms
0.5 50.0% 0.0% 80.0% Estimated
Probability_rehab_post_med_failure Probability exercise rehabilitation
post medication failure
0.85 85.0% 0.0% 95.0% Source: Cavanaugh JT, Killian SE.
Rehabilitation following meniscal
repair. Curr Rev Musculoskelet Med
2012;5:46-58.
Probability_rehab_success Probability rehab success post
meniscectomy
Probability_meniscal_repair_success 80.0% 0.0% 90.0% Source: Cavanaugh JT, et al. (2012).
TN_MRI True_negatives_MRI 90.0% 0.0% 95.0% Crawford R, et al. (2007).
TN_NA True_Negatives_NA 85.8% 0.0% 99.0% Based on VisionScope NA ﬁndings.
Source: Gill TJ, et al. (2018).
TP_MRI True_positives_MRI 82.5% 0.0% 90.0% Crawford R, et al. (2007).
TP_NA True_positives_NA 96.9% 0.0% 99.0% Based on VisionScope NA ﬁndings.
Source: Gill TJ, et al. (2018).
Weighted_average_complication_cost Weighted_average_cost_complication $12,804 $0 $20,000 Weighted average cost of DVT, PE, VTE,
readmit, wound complication based on
the probabilities of occurrence and
over a 12-month time frame. Derived
from the medical literature and
inﬂated to 2017.
Private Pay Distributions
Name Description Type Parameters EV Comment
Physical_therapy_duration_post_surg Physical therapy in weeks post
arthroscopic meniscal surgery
Uniform Subtype: 2; low: 3; high: 6 4.5 Assumed course of physical therapy
based on coverage determinations of
Medicare and private payers.
Cost_complication_VTE Cost of treating a VTE over a
12-month period: Medicare
Normal Mean: 25,730; SD: 40,250 $25,730 Source: Lin J, Lingohr-Smith M, Kowng
WJ. Incremental health care resource
utilization and economic burden of
venous thromboembolism recurrence
from a US payer perspective. Jrl Manag
Care Pharm 2014;20:174-186.
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Appendix Table 3. Continued
Private Pay Distributions
Name Description Type Parameters EV Comment
Weighted_average_cost_complication Weighted average cost of a
complication post arthroscopy
Normal Mean: 12,804, standard deviation: 10000 $12,804 Weighted average cost of DVT, PE, VTE,
readmit, wound complication based on
the probabilities of occurrence and
over a 12-month time frame. Derived
from the medical literature and
inﬂated to 2017.
Positive_ﬁndings_MRI Percentage of positive ﬁndings
on MRI vs total ﬁndings
Uniform Subtype: 2, low: 0.4, high: 0.7 55% Assumed positive ﬁndings for medial
meniscus pathology for MRI.
True_negatives_MRI Percentage of TNs of all negative
ﬁndings MRI (TN + FN)
Uniform Subtype: 2, low: 0.85, high: 0.95 90% Assumed negative ﬁndings for medial
meniscus pathology for MRI.
KOOS4_exercise_two_years KOOS4 at 2-year exercise group Triangular Min: 81.1, likeliest: 85, max: 98.5 88.2 Source: Kise NJ, et al. (2016).
HA_effectiveness HA effectiveness in relieving pain Triangular Min: 0.53, likeliest: 0.76, max: 0.98 75.7% Source: Concoff A, et al. (2017).
Probability_meniscal_repair_success Probability of meniscus repair
success post rehab
Uniform Subtype: 2, low: 0.7, high: 0.9 80.0% Source: Cavanaugh JT, et al. (2012.
NA_knee Private payer amount NA POS Normal Mean: 958, standard deviation: 317 $958 Data on ﬁle VisionScope; 400 plus data
points from private insurers.
Positive_ﬁndings_NA Percentage of positive ﬁndings
of all ﬁndings NA (TP + FP)
Uniform Subtype: 2, low: 0.4, high: 0.45 42.50% Source: Gill TJ, et al. (2018).
Probability_complication_knee_arthroscopy Probability of knee complication Triangular Min: 0.001, likeliest: 0.0095, max: 0.02 1.02% Probability of a complication based on all
complications summed up: 0.95%.
True_Negatives_NA Percentage of TNs NA of all
negatives (TN + FN)
Triangular Min: 0.725, likeliest: 0.882, max: 0.967 85.80% Source: Gill TJ, et al. (2018).
KOOS4_excercise_one_year KOOS4 at 1-year exercise Triangular Min: 74.9, likeliest: 79.5, max: 93.2 82.533 Source: Kise NJ, et al. (2016).
True_positives_NA Percentage of TPs of all positives
(TP + FP)
Triangular Min: 0.922, likeliest: 0.986, max: 1 96.93% Source: Gill TJ, et al. (2018).
True_positives_MRI Percentage of TPs of all positive
MRI ﬁndings (TP + FP)
Uniform Subtype: 2, low: 0.8, high: 0.85 82.50% Source: Crawford R, et al. (2007).
KOOS4_meniscectomy_two_years KOOS4 at 2-year meniscectomy Triangular Min: 80.4, likeliest: 84.1, max: 97.7 87.4 Source: Kise NJ, et al. (2016).
KOOS4_meniscectomy_one_year KOOS4 at 1-year meniscectomy Triangular Min: 79.9, likeliest: 83.7, max: 97.2 86.933 Source: Kise NJ, et al. (2016).
KOOS4_baseline KOOS4 baseline score meniscus
damage
Normal Mean: 56.95, standard deviation: 16.37 56.95 Source: Kise NJ, et al. (2016). Combined
mean from exercise and meniscectomy
groups: N ¼ 70 both groups. Mean 
SD exercise: 54.3  18.2 and
meniscectomy: 59.6  13.8.
MRI_knee Private payer rate MRI knee Normal Mean: 1628, standard deviation: 622 $1,628 Available from Truven Analytics.
CPT, Current Procedural Terminology; DVT, deep vein thrombosis; E&M, evaluation and management; EV, expected value; HA, hyaluronic acid; FN, false negative; FP, false positive; KOOS,
knee injury and osteoarthritis and outcome score; MRI, magnetic resonance imaging; NA, needle arthroscopy; PE, pulmonary embolism; POS, physician ofﬁce setting; SD, standard deviation;
TN, true negative; TP, true positive; VTE, venous thromboembolism.
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Appendix Figure 1. (continued).
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Appendix Figure 1. (continued).
COST-EFFECTIVENESS OF NEEDLE KNEE ARTHROSCOPY 562.e13
